Loading
Inovio Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Kim Jong Joseph, was filed 13 Jan 2020.
Inovio Pharmaceuticals, Inc.: what insiders have been doing
Inovio Pharmaceuticals, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). From 22 October 2025 to 22 October 2026, the disclosure feed for Inovio Pharmaceuticals, Inc. logged 18 filings by 5 insiders.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Insider buying of Inovio Pharmaceuticals, Inc. has been absent for the past year. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4.
With 18 filings in twelve months, the company is quieter than the median of 24 filings across the 3,171 companies we follow on the same exchange. The full history, which starts in 2016, counts 10 purchases against 74 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 65,343 USD and net income at -84.9 m USD.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
453
Thresholds
n/a
Buy Volume
€899,145
10 ops. · all time
Sell Volume
€17M
74 ops. · all time
Since the insiders bought
- +180.5%Entry US$39.48 · Close at T+365 US$110.76
- +345.1%Entry US$25.80 · Close at T+365 US$114.84
- -28.3%Entry US$78.84 · Close at T+365 US$56.52
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.01
Analyst consensus
3 analysts2.67/5
US$2.50Target US$3.17(+215%)US$4.00
Income statement
RevenueUS$65.3k
EBITDA-US$82M-125426% margin
Net income-US$84.9M-130000.0% margin
Valuation
PER (forward)-2.3x
P/Book19.0x
Beta1.61
Balance sheet & cash
Market capUS$103.9M
Total debtUS$9.4M
Free Cash Flow-US$88.9M
Debt / Equity183%
Profitability & ownership
ROE-409.9%
ROA-84.2%
% insiders0.3%
% institutions46.1%
Last declaration on 1 April 2026
Declarations453 total
1,223 shares@ US$1.74100.0% of flowCommon StockSEC:0001936799-26-000004:1
4,292 sharesCommon StockSEC:0001936799-26-000004:0
10,634 sharesCommon StockSEC:0001259780-26-000002:2
28,401 sharesCommon StockSEC:0001771498-26-000002:2
7,366 sharesCommon StockSEC:0001770390-26-000002:2
11,550 sharesCommon StockSEC:0001936799-26-000002:1
2,965 shares@ US$1.790.2% of flowCommon StockSEC:0001259780-26-000002:1
6,294 shares@ US$1.790.4% of flowCommon StockSEC:0001259780-26-000002:3
8,057 shares@ US$1.790.5% of flowCommon StockSEC:0001771498-26-000002:1
13,657 shares@ US$1.790.9% of flowCommon StockSEC:0001771498-26-000002:3
2,064 shares@ US$1.790.2% of flowCommon StockSEC:0001770390-26-000002:1
3,034 shares@ US$1.790.3% of flowCommon StockSEC:0001770390-26-000002:3
3,903 shares@ US$1.7966.2% of flowCommon StockSEC:0001936799-26-000002:2
18,632 sharesCommon StockSEC:0001771498-26-000002:0
5,010 sharesCommon StockSEC:0001770390-26-000002:0
972 sharesCommon StockSEC:0001669080-26-000002:0
5,010 sharesCommon StockSEC:0001936799-26-000002:0
5,010 sharesCommon StockSEC:0001259780-26-000002:0
2,916 sharesCommon StockSEC:0001055726-25-000046:0
2,167 sharesCommon StockSEC:0001055726-25-000034:0
2,167 sharesCommon StockSEC:0001055726-25-000040:0
2,167 sharesCommon StockSEC:0001055726-25-000032:0
2,167 sharesCommon StockSEC:0001055726-25-000037:0
2,167 sharesCommon StockSEC:0001055726-25-000038:0
2,167 sharesCommon StockSEC:0001055726-25-000039:0
25 of 453 declarations
About Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. (ticker: INO) is a U.S.-listed biotechnology company trading on NASDAQ in the United States, with corporate headquarters in Plymouth Meeting, Pennsylvania. INOVIO is focused on developing and commercializing DNA medicines, a differentiated platform designed to help the body produce therapeutic proteins through engineered DNA plasmids delivered by the company’s proprietary CELLECTRA devices. For international equity investors, this is best viewed as a clinical-stage biotech story with meaningful scientific optionality, but also high dependence on trial data, regulatory decisions, and financing execution. ([ir.inovio.com](https://ir.inovio.com/overview/default.aspx?utm_source=openai))
Founded in 1983, INOVIO has spent decades building a platform around DNA medicine design and electroporation-based delivery. The company’s historical and current focus spans HPV-related diseases, cancer, and infectious diseases. Its pipeline includes multiple clinical and preclinical programs, but the clear lead asset is INO-3107, being developed for recurrent respiratory papillomatosis (RRP), a rare HPV-related disease of the respiratory tract that often requires repeated surgeries. INOVIO has said INO-3107 could become its first commercial product and potentially the first DNA medicine approved in the United States. ([ir.inovio.com](https://ir.inovio.com/news/news-details/2025/INOVIO-Completes-Rolling-BLA-Submission-Seeking-Accelerated-Approval-for-INO-3107-as-a-Treatment-for-RRP-in-Adults/default.aspx?utm_source=openai))
Read moreShow less
From a competitive standpoint, INOVIO occupies a niche position within biotech. Its main differentiator is a proprietary DNA medicines platform that uses plasmid design plus a delivery device rather than viral vectors or lipid nanoparticles. That gives the company a distinct scientific narrative and a potentially broad technology base, but the investment case remains binary in many respects: platform value will be judged by whether the lead program can achieve regulatory success and whether the company can convert its science into commercial execution. The company also highlights partnerships and collaborations, which can help offset development cost and expand credibility. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1055726/000105572625000026/ino-20250331.htm?utm_source=openai))
Geographically, INOVIO remains heavily U.S.-centric. Its headquarters are in Pennsylvania, its 2025 revenue was earned entirely in the United States, and all of its long-lived assets are located in the U.S. That profile underscores a domestic operating base, even though the company’s disease targets and eventual commercial opportunities may have global relevance. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm?utm_source=openai))
The most important recent development is regulatory: in December 2025, the FDA accepted the Biologics License Application for INO-3107 for review under the accelerated approval pathway and assigned a PDUFA target date of October 30, 2026. In April 2026, INOVIO said the FDA’s mid-cycle review did not raise new major issues, while also noting that the agency had preliminarily questioned eligibility for accelerated approval. For investors, this is the key near-term catalyst and the main event to watch, because it could determine whether INOVIO transitions from a development-stage company into a commercial-stage one. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000018/ino-20260331.htm?utm_source=openai))
